Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-02
2010-10-19
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07816366
ABSTRACT:
The invention encompasses protectant agents including uracil or a metabolite thereof that effectively prevent and/or treat the cutaneous toxicities and dermatological side-effects associated with chemotherapeutic agents. Additionally, and surprisingly compositions including uracil or a metabolite thereof are effective for treating or preventing various dermatoses.
REFERENCES:
patent: 5326764 (1994-07-01), Milstone et al.
patent: 6979688 (2005-12-01), Ford
patent: 6995165 (2006-02-01), Ford
patent: 7368456 (2008-05-01), Ford
patent: 7662829 (2010-02-01), Ford
patent: 2003/0158128 (2003-08-01), Ford
[R] Barrows, parts of “Antineoplastic and Immunoactive Drugs,” Chapter 86 in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro et al. (eds.), Lippincott, Williams & Wilkins, Baltimore, MD, 2000, only pp. 1498 and 1815 supplied.
Cao, S. et al., “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathwya Modulaiton in Therapy of Colorectal Cancer”, Clinical Cancer Research, vol. 1, pp. 839-845, Aug. 1995.
Spicer et al., “Toxicity Study of Uracil in Dogs”, Journal of Applied Toxicology, vol. 5 (1985), pp. 199-204.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 12/073,424, Dec. 12, 2008, 12 pgs.
John P. Ford, U.S. PTO Notice of Allowance, U.S. Appl. No. 12/073,424, Oct. 13, 2009, 10 pgs.
John P. Ford, U.S. PTO Notice of Allowance, U.S. Appl. No. 11/196,921, Dec. 12, 2007, 16 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/196,921, Aug. 17, 2007, 10 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/196,921, Nov. 29, 2006, 13 pgs.
Hirata Koichi et al., “Pharmacokinetic Study of S-1, a Novel Oral Fluorouracil Antitumor Drug”, Clinical Cancer Research, vol. 5 (1999), pp. 2000-2005.
J.L. Fischel et al., “Experimental Arguments for a Better Understanding of Hand-Foot Syndrome Under Capecitabine”, Proceedings of the American Association for Cancer Research, vol. 45, (2004), p. 487 (Abstract #2119).
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 10/918,199, Feb. 2, 2005, 20 pgs.
John P. Ford, U.S. PTO Notice of Allowance, U.S. Appl. No. 10/918,199, Sep. 16, 2005, 13 pgs.
J.M. Hageboutrous et al., “Life threatening toxicity in a dihyropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil”, Clinical Cancer Research, vol. 5 (1999), pp. 2006-2011.
D. Hatfield et al., “Synthesis of (3-Ribosyluric Acid) 5′-Phosphate and (3-Ribosylxanthine) 5′-Phosphate by a Pyrimidine Ribonucleotide Pyrophosphorylase of Beef Erythrocytes”, The Journal of Biological Chemistry, Aug. 1964, pp. 60-66.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 10/684,203, Jun. 7, 2004, 9 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 10/684,203, Dec. 8, 2004, 18 pgs.
John P. Ford, U.S. PTO Notice of Allowance, U.S. Appl. No. 10/684,203, Mar. 17, 2005, 9 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 10/364,383, Aug. 28, 2003, 7 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 10/364,383, Jun. 7, 2004, 7 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/146,883, Apr. 29, 2010, 7 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/146,883, Aug. 17, 2009, 6 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/146,883, Jul. 9, 2008, 6 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/146,883, Oct. 25, 2007, 5 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 11/146,883, Nov. 29, 2006, 5 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 12/071,648, Jun. 30, 2009, 10 pgs.
John P. Ford, U.S. PTO Office Action, U.S. Appl. No. 12/071,648, Oct. 9, 2008, 10 pgs.
Caco, S. et al., “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathway Modulation in Therapy of Colorectal Cancer,” Clinical Cancer Research, Aug. 1995, vol. 1, pp. 839-845.
Childress, J. et al., “Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy,” American Journal of Clinical Oncology, Oct. 2003, vol. 26(5), pp. 435-436.
Chua, D. et al., “Efficacy of Capecitabine Monotherapy in Patients with recurrent and Metastic Nasopharyngeal Carcinoma Pretreated with Platinum-Based Chemotherapy,” 2003, Proc, Am Soc. Clin. Oncol., vol. 22, p. 511.
Ehrlanger et al., Cutaneous Absorption and Urinary Excretion of 6-14C-5-5-Fluorouracil Ointment Applicated in an Ointment to Healthy and Diseased Human Skin, Dermatologica, 1970, vol. 140, Suppl. 1., pp. 129-136.
Elasmer et al. “Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1”, Jpn. J. Clin. Oncol., 2001, vol. 3(4), pp. 172-174.
Findlay, M. et al., “Measurement and Plasma 5-Fluorouracil By High-Performance Liquid Chromatography with Comparison of Results to Tissue Drug Levels Observed Using in Vivo 19F Magnetic Resonance Spectroscopy in Patients in Protracted Venous Infusion With or Without Interferon-α,” Annals of Oncology, 1996, vol. 7(47-53), pp. 111-117.
Fischel, J-L. et al., “Experimental Arguments for a Better Understanding of Hand-Foot Syndrome Under Capecitabine,” Proceedings of the American Association for Cancer Research, Mar. 2004, vol. 45, p. 487 (Abstract #2119).
Fuji, S. et al., “Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents,” Gann, 70, Apr. 1979, pp. 209-214.
Fukushima, S. et al., “Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and 1 Rationale,” Cancer Research 52, Apr. 1, 1992, pp. 188-193.
Gallo, R. et al., The Enzymatic Mechanisms for Deoxthymidine Synthesis in Human Leukocites, The Journal of Clinical Investigation, 1969, vol. 48, pp. 82-93.
Goodman & Gillman, The Pharmacological Basis of Therapeutics, 9th Edition, 1996, pp. 1225-1229.
Hartmann, H.R. et al., “Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine,” Med. Oncol. & Tumor Pharmacother, Apr. 25, 1986, vol. 3(2), pp. 111-118.
Hejna, M. et al., “Decrease of Duration and Symptoms in Chemotherapy-Induced Oral Mucositis by Topical GM-CSF: Results of a Prospective Randomised Trial”, European Journal of Cancer, Nov. 2001, vol. 37(16), pp. 1994-2002.
Hirata, K. et al., Pharmacokinetic Study of S-1, a Novel Oral Fluorouracil Antitumor Drug, Clinical Cancer Research, Aug. 1999, pp. 2000-2005, vol. 5.
Hoff, P., “The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL™) and S-1: A Review of Their Clinical Development and Therapeutic Potential,” Investigational New Drugs 18, 2000, pp. 163-163.
Ichikawa, W. et al., “Polymorphins of Orotate Phosphoribosyl Transferase (OPRT) Gene and Thymidylate Synthase Tandem Repeat (TSTR) Predic Advese Events (AE) in Colorectal Cancer (CRC) Patients Treated with 5-Fluorouracil (FU) Pluis Leucovorin (LV),” Gastrointestinal Cancer, 2003, p. 1063.
Ichikawa, W. et al., “Both Gene Expression for Orotate Phosphoribosyltransferase and Its Ratio to Dihydropyrimidine Dehydrogenase Influence Outcome Following Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal Cancer,” British Journal of Cancer, (2003), 89 2003 Cancer Research UK.
Ikenaka, K. et al., “Effect of Uracil on Metabolism of 5-fluorouracil in Vitro,” Gann, 70, Jun. 1979, pp. 353-359.
Johnson, M. et al., “Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient after Treatment with Topical 5-Fluorouracil,” Clinical Cancer Research, Aug. 1999, vol. 5, pp. 141-146.
Kawaguchi, Y. et al., “Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats,” Gann, 71, Dec. 1980, pp. 889-899.
Leo, S. et al., “Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil,&#
Asymmetric Therapeutics, LLC
Crane Lawrence E
Fanelli Dean L.
Fanelli Strain & Haag PLLC
LandOfFree
Compositions and methods for treating and preventing dermatoses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating and preventing dermatoses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating and preventing dermatoses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236391